

RECEIVED  
JUL 19 2003  
TECH CENTER 100/2300

Claim 2, line 1, Change "Use of the compounds" to --The method--.


### REMARKS

By the above amendments, Applicants have placed the claims in a more acceptable US format.

In response to the election of species requirement, Applicants elect, with traverse, the compound of formula  $A-X_1-NO_2$ , wherein  $A=R(COX)_t$ ,  $t=1$ ,  $x=0$  and R is the residue of indomethacin. See page 76 and 88 of the claims.

Claims 1, 2 and 5 read on the elected species.

Applicants understand that it is entitled to have addition species considered in this application where the Office does not find the elected species unpatentable. In addition, applicants reserve the right to file one or more divisional application directed to the non-elected claims.

 Finally, the restriction requirement is traversed. No objection as to unity of invention was raised during the International stage of this application. The inventive concept relates to the  $NO_2$  group attached to the compound through the bivalent connecting bridge  $X_1$ , as defined in claim 1. These compounds are effective in the treatment of urinary incontinence with reduced side effects relative to the prior art compounds. See pages 1-6 of the specification. Administration of the compounds does not lead to tachyphylaxis.

Accordingly, an early examination and an early action on the merits are respectfully requested. In the event this paper is not considered to be timely filed, Applicants respectfully petition for an appropriate extension of time. Any fees for such an extension, together with any additional fees which may be due with respect to this paper, may be charged to our Deposit Account No.01-2300.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC



James A. Poulos, III  
Attorney for Applicants  
Registration No. 31,714

Atty. Docket No. 108907-09002

1050 Connecticut Avenue, N.W., Suite 600  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000

POU:kga